Use of a polyphenol for the treatment of actinic keratosis

• US 20050079235A1
• Filed: 10/09/2003
• Published: 04/14/2005
• Est. Priority Date: 10/09/2003
• Status: Abandoned Application

• Current Assignee: Medigene AG
• Original Assignee: Medigene AG
• Inventors: Stockfleth, Eggert
• Application Number:
  US10/682,612
• Publication Number:
  US 20050079235A1
• Time in Patent Office: Days
• US Class Current: 424/729
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/353 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 36/82 Theaceae (Tea family), e.g. camellia
• CPC Class Codes: A61K 38/21 Interferons [IFN]
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention refers to a method for treating actinic keratosis by administering a pharmaceutically effective amount of a polyphenol to a patient as well as to the production of a medicament thereto.

Claims

1. A method for treating actinic keratosis by administering a pharmaceutically effective amount of a polyphenol to a patient.

2. The method according to claim 1, wherein the patient is a human.

3. The method according to claim 1, wherein the polyphenol is isolated from tea.

4. The method according to claim 1, wherein the polyphenol is extracted from a tea.

5. The method according to claim 9, wherein the tea is a green tea.

6. The method according to claim 1, wherein the polyphenol is isolated from a tea extract.

7. The method according to claim 1, wherein the polyphenol is selected from the group consisting of catechol, catechol gallate, epicatechol, epicatechol gallate, epigallocatechol, epigallocatechol gallate, gallocatechol and gallocatechol gallate.

8. The method according to claim 1, wherein the polyphenol has the general formula (I)

9. The method according to claim 7, wherein the catechol has the general formula (II)

10. The method according to claim 7, wherein the catechol is selected from the group consisting of of (+)-catechol, (−

)-catechol, (−

)-catechol gallate, (+)-epicatechol, (−

)-epicatechol, (−

)-epicatechol gallate, (−

)-epigallocatechol, (−

)-epigallocatechol gallate, (+)-gallocatechol, (−

)-gallocatechol and (−

)-gallocatechol gallate.

11. The method according to claim 1, wherein the polyphenol is present in the form of a mixture of polyphenols.

12. The method according to claim 11, wherein the mixture of polyphenols is a tea extract.

13. The method according to claim 12, wherein the tea extract is a green tea extract.

14. The method according to claim 12, wherein the mixture of polyphenols is selected from the group consisting of catechol, catechol gallate, epicatechol, epicatechol gallate, epigallocatechol, epigallocatechol gallate, gallocatechol and gallocatechol gallate.

15. The method according to claim 14, wherein the catechols are selected from the group consisting of (−

)-epicatechol, (−

)-epicatechol gallate, (−

)-epigallocatechol, (−

)-epigallocatechol gallate, (+)-gallocatechol and (−

)-gallocatechol gallate.

16. The method according to claim 14, wherein the catechols are selected from the group consisting of about 2-20% (w/w) epicatechol, about 2-20% (w/w) epicatechol gallate, about 1-25% (w/w) epigallocatechol, about 40-75% (w/w) epigallocatechol gallate, about 0.05-5% (w/w) gallocatechol and about 0.5-20% (w/w) gallocatechol gallate.

17. The method according to claim 14, wherein the catechols are selected from the group consisting of about 10.8% (w/w) of epicatechol, about 6.5% (w/w) of epicatechol gallate, about 9.2% (w/w) of epigallocatechol, about 54.8% (w/w) of epigallocatechol gallate and about 4.0% (w/w) of gallocatechol gallate.

18. The method according to claim 14, wherein the mixture contains about 10.8% (w/w) of (−

)-epicatechol, about 6.5% (w/w) of (−

)-epicatechol gallate, about 9.2% (w/w) of (−

)-epigallocatechol, about 54.8% (w/w) of (−

)-epigallocatechol gallate and about 4.0% (w/w) of (−

)-gallocatechol gallate.

19. The method according to claim 14, wherein the catechols are selected from the group consisting of about 2-12% (w/w) epicatechol, about 4-15% (w/w) epicatechol gallate, about 1-8% (w/w) epigallocatechol, about 60-68% (w/w) epigallocatechol gallate, about 0.05-1% (w/w) gallocatechol and about 1-7% (w/w) gallocatechol gallate.

20. The method according to claim 14, wherein the catechols are selected from the group consisting of about 5-8% (w/w) epicatechol, about 5-7% (w/w) epicatechol gallate, about 2-3% (w/w) epigallocatechol, about 61-65% (w/w) epigallocatechol gallate and about 2-4% (w/w) of gallocatechol gallate.

21. The method according to claim 14, wherein the catechols are selected from the group consisting of about 5-8% (w/w) epicatechol, about 5-6% (w/w) epicatechol gallate, about 6-8% (w/w) epigallocatechol, about 61-65% (w/w) epigallocatechol gallate and about 2-4% (w/w) of gallocatechol gallate.

22. The method according to claim 1, wherein the polyphenol is combined with an additive.

23. The method according to claim 22, wherein the additive is selected from the group consisting of petroleum jelly, wax, oleyl alcohol, propylene glycol monostearate, propylene glycol monopalmitostearate and isopropyl myristate.

24. The method according to claim 1, wherein the polyphenol is administered topically.

25. The method according to claim 1, wherein the polyphenol is contained in a carrier selected from the group consisting of an emulsion, a gel, a cream and an ointment.

26. The method according to claim 1, wherein the method for treating actinic keratosis is combined with a different anticancer treatment.

27. The method according to claim 26, wherein the different anticancer treatment is selected from the group consisting of surgery, electrodessication, curettage, excision, Mohs micrographic surgery, radiation, proton therapy, chemotherapy, photodynamic therapy, cryosurgery, laser, immunotherapy, vaccine therapy and biologic therapy.

28. The method according to claim 27, wherein the chemotherapy is carried out with an agent selected from the group consisting of podophyllin, 5-fluorouracil, bleomycin, interferon, imiquimod, and mixtures thereof.

29. The method according to claim 27, wherein the radiation is selected from the group consisting of X-ray radiation and γ

-radiation.